Research
Lo, Andrew W. (2018), Why Robo-Advisors Need Artificial Stupidity, RISK, July 20.
View abstract
Hide abstract
‘Fintech’ is transforming the financial sector at a pace that is now obvious even to the casual observer. We see this not only in daily headlines about initial coin offerings or financial applications of blockchain technology, but also in the daily experiences of the average consumer: paper cheques consigned forever to desk drawers, automatic currency conversions on a trip abroad, the rapid approval of an online loan – and most excitingly for some, personal investing.
Lo, Andrew W. (2018), Financial Risks Don’t Go on Holiday, RISK, August 20.
View abstract
Hide abstract
August is typically when Wall Street goes to the beach, the mountains, or just home to recharge for a week or two. Many Europeans take the entire month off. But financial markets have a cruel knack of ruining holidays. As we lie in our hammocks this August, we might do well to recall a remarkable event that occurred, seemingly without warning, 11 years ago this month in the run-up to the financial crisis.
Lo, Andrew W. (2018), Cryptocurrencies: King’s Ransom or Fool’s Gold?, RISK, October 2.
View abstract
Hide abstract
The increasing dominance of technology in daily lives is finally penetrating the financial industry as well. The growing popularity of algorithmic trading, mobile payment platforms and robo-advisers is just the beginning of the fintech revolution. But perhaps the most radical - and controversial - innovation in today's headlines is cryptocurrencies. Extreme volatility makes products an unreliable store of value - for now.
Lo, Andrew W. (2018), All the News that’s Fit to Print, RISK, October 25.
View abstract
Hide abstract
The information revolution has transformed everyday life for billions of people throughout the world. For example, according to mobile phone research group GSMA Intelligence, there are currently over 5 billion unique mobile phone subscribers, out of an estimated global population of 7.6 billion. This is the equivalent of a mobile phone for every person on the planet between the ages of 15 and 65.
Lo, Andrew W. (2018), Doing Well by Doing Good, RISK, December 12.
View abstract
Hide abstract
In the past decade, financial industry excesses have been cited as the source of many ills afflicting economies and political systems in the West. But, if used responsibly, finance could help provide the cure for some of humanity’s most pressing problems – from cancer to fossil fuel depletion and climate change.
Why Artificial Intelligence May Not Be As Useful or As Challenging As Artificial Stupidity
Lo, Andrew W. (2019), Why Artificial Intelligence May Not Be As Useful or As Challenging As Artificial Stupidity, Harvard Data Science Review 1 (1).
View abstract
View abstract
Hide abstract
In response to the senators January 21, 2016 request for comment on their Sovaldi report, February 27, 2016. On behalf of all patients and their family members and friends, thank you for conducting the study on the pricing strategy of Gilead Sciences and shining a spotlight on the issue of drug pricing. When access to life-saving therapies is limited by affordability, important moral and ethical issues must be considered in addition to economic and political ones. For too long, we in the United States have ignored these issues for fear of “death panels” and difficult end-of-life decisions. But the growing number of breakthrough therapies and the rising cost of healthcare will soon force us to confront these issues directly. Your report and is an important step in helping us to develop a rational, ethical approach to dealing with this looming challenge.
Lo, Andrew W. (2014), Macroeconomic Modeling and Financial Stability: Lessons from the Crisis, Banking Perspective 2, 22–31.
View abstract
Hide abstract
The dynamic stochastic general equilibrium model (DSGE) marked a major milestone by capturing the dynamic change of economic variables over time. However, many DSGE models were exposed as having omitted critical structural linkages relevant to the financial crisis. To address these deficiencies, existing DSGE models should be enhanced to better incorporate the role of the financial sector and financial markets. In addition, these models should reexamine key micro-foundations of the model and consider behavioral components.
Lo, Andrew W., and Roger M. Stein (2014), To Cure Cancer, A Profit Motive, Scientific American SA Forum, March 26.
View abstract
Hide abstract
Translating scientific research into safe and effective drugs takes money—lots of money. Current estimates put the cost of developing a single successful drug at more than $2 billion by the time you include all the dead ends along the way; the out-of-pocket cost for just a single attempt is about $200 million. Drug development usually takes a decade or longer, and the probability of success is low (historically around 5 percent for oncology). As a result, investors are now shying away from the pharmaceutical industry, investing instead in less risky and more attractive opportunities like big data, social media and e-commerce. Financial engineering techniques can help change that, directing capital from those wishing to invest it to those who need it to develop new drugs.
with
, Fojo, Tito, and Andrew W. Lo (2016), Price, Value, and the Cost of Cancer Drugs, Lancet Oncology 17 (1), 3–5.
View abstract
Hide abstract
The reports by Wim van Harten and colleagues and Sabine Vogler and colleagues in The Lancet Oncology on the costs of cancer drugs in European countries deserve special attention from all oncology and biopharmaceutical stakeholders. van Harten identified that, in 15 European countries, list prices can be up to 92% lower than the highest reported, with actual prices paid up to 58% lower. These findings are backed up by Vogler and colleagues' study 2 in 16 European countries, Australia, and New Zealand, which documented that highest-minus-lowest list price differences ranged from 28% to 388% for cancer drugs. Such variability argues strongly for greater transparency in drug pricing and the circumstances leading to such differences. But most importantly, it underscores the need to establish the true value of cancer therapies, and those who have championed this cause have been handed unequivocal evidence confirming what they have long suspected: drug prices are typically driven by what the market will bear.